Decoy receptors block TRAIL sensitivity at a supracellular level: The role of stromal cells in controlling tumour TRAIL sensitivity

Oncogene

Volumn 35, Issue 10, 2016, Pages 1261-1270

  O'Leary, L ^a,f   Van Der Sloot, A M ^b,c   Reis, C R ^d,g   Deegan, S ^a   Ryan, A E ^a   Dhami, S P S ^a   Murillo, L S ^a   Cool, R H ^d   De Sampaio, P Correa ^e,h   Thompson, K ^a   Murphy, G ^e   Quax, W J ^d   Serrano, L ^b   Samali, A ^a   Szegezdi, E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DECOY RECEPTOR 2; GAMMA INTERFERON; GLUTAMIC ACID; GLYCINE; INTERLEUKIN 6; INTERLEUKIN 8; LEUCINE; MUTANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; THREONINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; TNFRSF10C PROTEIN, HUMAN; TNFRSF10D PROTEIN, HUMAN; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

AMINO ACID SUBSTITUTION; APPARENT DISSOCIATION CONSTANT; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL MODEL; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR SENSITIVITY; SITE DIRECTED MUTAGENESIS; STROMA CELL; SURFACE PLASMON RESONANCE; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PROTEIN CONFORMATION; TUMOR CELL LINE;

CELL LINE, TUMOR; GPI-LINKED PROTEINS; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROTEIN CONFORMATION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 10C; STROMAL CELLS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 84960795612     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.180     Document Type: Article

References (46)

1. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2: 241-243.
2. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12: 611-620.
3. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.
4. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-14367.
5. Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 2009; 35: 280-288.
6. Kim K, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z et al. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 2005; 33: 541-548.
7. Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P et al. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer 2011; 117: 1172-1182.
8. Luce A, Courtin A, Levalois C, Altmeyer-Morel S, Romeo PH, Chevillard S et al. Death receptor pathways mediate targeted and non-targeted effects of ionizing radiations in breast cancer cells. Carcinogenesis 2009; 30: 432-439.
9. Shareef MM, Cui N, Burikhanov R, Gupta S, Satishkumar S, Shajahan S et al. Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Res 2007; 67: 11811-11820.
10. Wilson NS, Yang A, Yang B, Couto S, Stern H, Gogineni A et al. Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer Cell 2012; 22: 80-90.
11. Shirley S, Morizot A, Micheau O. Regulating TRAIL receptor-induced cell death at the membrane: a deadly discussion. Recent Pat Anticancer Drug Discov 2011; 6: 311-323.
12. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006; 26: 7046-7055.
13. Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 2005; 102: 18099-18104.
14. Ganten TM, Sykora J, Koschny R, Batke E, Aulmann S, Mansmann U et al. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med 2009; 87: 995-1007.
15. Koksal IT, Sanlioglu AD, Karacay B, Griffith TS, Sanlioglu S. Tumor necrosis factorrelated apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol Oncol 2008; 26: 158-165.
16. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005; 90: 612-624.
17. Chamuleau ME, Ossenkoppele GJ, van Dreunen L, Jirka SM, Zevenbergen A, Schuurhuis GJ et al. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. Leuk Res 2011; 35: 741-749.
18. Dyer MJ, MacFarlane M, Cohen GM. Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol 2007; 25: 4505-4506.
19. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59: 2747-2753.
20. van Dijk M, Halpin-McCormick A, Sessler T, Samali A, Szegezdi E. Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways. Cell Death Dis 2013. 4.
21. Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 1999; 59: 2770-2775.
22. Schneider P, Olson D, Tardivel A, Browning B, Lugovskoy A, Gong D et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 2003; 278: 5444-5454.
23. Tur V, van der Sloot AM, Reis CR, Szegezdi E, Cool RH, Samali A et al. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J Biol Chem 2008; 283: 20560-20568.
24. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA 2006; 103: 8634-8639.
25. Reis CR, Van der Sloot AM, Natoni A, Szegezdi E, Setroikromo R, Meijer M et al. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis 2010; 1: e83.
26. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res 2005; 33: 382-388.
27. Szegezdi E, Van der Sloot AM, Mahalingam D, O' Leary L, Cool RH, Munoz IG et al. Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL. Mol Cell Proteomics 2012. 11.
28. Correa de Sampaio P, Auslaender D, Krubasik D, Failla AV, Skepper JN, Murphy G et al. A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis. PLoS One 2012; 7: e30753.
29. Finnberg N, Klein-Szanto AJP, E-D. WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008; 118: 111-123.
30. Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ 2014; 21: 1350-1364.
31. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
32. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013; 5: 171ra17.
33. Wang Q, Wang X, Hernandez A, Hellmich MR, Gatalica Z, Evers BM. Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem 2002; 277: 36602-36610.
34. Boland K, Flanagan L, Prehn JHM. Paracrine control of tissue regeneration and cell proliferation by caspase-3. Cell Death Dis 2013; 4: e725.
35. Cullen SP, Henry CM, Kearney CJ, Logue SE, Feoktistova M, Tynan GA et al. Fas/CD95-induced chemokines can serve as "find-me" signals for apoptotic cells. Mol Cell 2013; 49: 1034-1048.
36. Perez-Garijo A, Fuchs Y, Steller H. Apoptotic cells can induce non-autonomous apoptosis through the TNF pathway. Elife 2013; 2: e01004.
37. Roulston A, Marcellus RC, Branton PE. Viruses and apoptosis. Annu Rev Microbiol 1999; 53: 577-628.
38. Furth PA, Bar-Peled U, Li M. Apoptosis and mammary gland involution: reviewing the process. Apoptosis 1997; 2: 19-24.
39. Ivanov VN, Hei TK. A role for TRAIL/TRAIL-R2 in radiation-induced apoptosis and radiation-induced bystander response of human neural stem cells. Apoptosis 2014; 19: 399-413.
40. Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 2007; 69: 716-723.
41. Mahalingam D, Natoni A, Keane M, Samali A, Szegezdi E. Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. Br J Cancer 2010; 102: 754-764.
42. Szegezdi E, van der Sloot AM, Mahalingam D, O'Leary L, Cool RH, Munoz IG et al. Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL. Mol Cell Proteomics 2012; 11: 013730.
43. Szegezdi E, Reis CR, van der Sloot AM, Natoni A, O'Reilly A, Reeve J et al. Targeting AML through DR4 with a novel variant of rhTRAIL. J Cell Mol Med 2011; 15: 2216-2231.
44. Ander M, Beltrao P, Di Ventura B, Ferkinghoff-Borg J, Foglierini M, Kaplan A et al. SmartCell, a framework to simulate cellular processes that combines stochastic approximation with diffusion and localisation: analysis of simple networks. Syst Biol (Stevenage) 2004; 1: 129-138.
45. Dublanche Y, Michalodimitrakis K, Kummerer N, Foglierini M, Serrano L. Noise in transcription negative feedback loops: simulation and experimental analysis. Mol Syst Biol 2006; 2: 41.
46. Milo R, Jorgensen P, Moran U, Weber G, Springer M. BioNumbers - the database of key numbers in molecular and cell biology. Nucleic Acids Res 2010; 38: D750-D753.